Oct. 2016: Celgene (Stock to Study), Amgen (Undervalued)The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Celgene Corporation (NDQ: CELG) as its October 2016 "Stock to Study" and Amgen Inc. (NDQ: AMGN), as its October 2016 "Undervalued Stock" for investors' informational and educational use.
"The committee selected Celgene for its high growth potential of cancer-treatment drugs in coming years coupled with a reasonable valuation," said Adam Ritt, editor of BetterInvesting Magazine. "For the Undervalued selection, the committee cited as catalysts Amgen's phase three trails for cholesterol and migraine drugs and the cessation of a royalty payment to Pfizer in October."
Check BetterInvesting's October issue for more details about these selections. Go to the trial version of BetterInvesting's online tools to study the investment potential of Celgene and Amgen by viewing their fundamental data and applying judgments.
Committee members are Kenneth M. Bernard, CFA; Robert M. Bilkie, Jr., CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip S. Dano, CFA; Donald E. Danko, CFA; Maury Elvekrog, CFA; and Walter J. Kirchberger, CFA.
As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors and are not intended as investment recommendations. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.